相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2021)
Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement
Emanuele Damiano Luca Urso et al.
DIGESTIVE AND LIVER DISEASE (2021)
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
F. Pietrantonio et al.
ESMO OPEN (2021)
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
S. Bellone et al.
ANNALS OF ONCOLOGY (2021)
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Daniele Fanale et al.
CANCERS (2021)
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Dana M. Rogue et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2021)
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes
Luigi Magrin et al.
ONCOGENE (2021)
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Yoland Antill et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting
Umberto Malapelle et al.
CELLS (2021)
Molecular Pathology of Colorectal Cancer
Shuko Harada et al.
ADVANCES IN ANATOMIC PATHOLOGY (2020)
Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
Yuji Eso et al.
JOURNAL OF GASTROENTEROLOGY (2020)
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients
Mina Nikanjam et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
Christoph Fraune et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment
Romain Cohen et al.
BULLETIN DU CANCER (2020)
Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.
Joseph Chao et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Are patients with ulcerative colitis still at increased risk of colon cancer?
Oriana M. Damas et al.
LANCET (2020)
Checkpoint inhibitor immunotherapy in kidney cancer
Wenxin Xu et al.
NATURE REVIEWS UROLOGY (2020)
Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population
Angelica Petrillo et al.
ONCOTARGETS AND THERAPY (2020)
Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability
Hailong Jin et al.
ONCOTARGETS AND THERAPY (2020)
Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report
Giuseppe Tirino et al.
FRONTIERS IN ONCOLOGY (2020)
Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications
Bjoern Schneider et al.
CLINICAL GENITOURINARY CANCER (2020)
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
Masahiro Kagabu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
Nils Homann et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
Jwa Hoon Kim et al.
CANCER RESEARCH AND TREATMENT (2020)
An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome
Cuong V. Nguyen et al.
JAMA DERMATOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
Maria Lorenzi et al.
JOURNAL OF ONCOLOGY (2020)
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma
M. J. M. van Velzen et al.
CANCER TREATMENT REVIEWS (2020)
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
Novel Biocartis Idylla™ cartridge-based assay for detection of microsatellite instability in colorectal cancer tissues
Andres E. Mindiola-Romero et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study
Umberto Malapelle et al.
CELLS (2020)
Candidate Gene Discovery in Hereditary Colorectal Cancer and Polyposis Syndromes-Considerations for Future Studies
Iris B. A. W. te Paske et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
Lorena Incorvaia et al.
ONCOIMMUNOLOGY (2020)
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers
Yuji Eso et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Advances in immunotherapy for colorectal cancer: a review
Gol Golshani et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti et al.
CELLULAR IMMUNOLOGY (2019)
Epidemiology of Renal Cell Carcinoma
Umberto Capitanio et al.
EUROPEAN UROLOGY (2019)
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1
Lola Fashoyin-Aje et al.
ONCOLOGIST (2019)
Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy
Mary M. Mullen et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Pancreatic Adenocarcinoma, Version 1.2019
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
Benjamin Bian et al.
ONCOIMMUNOLOGY (2019)
Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
Cong Chen et al.
ONCOIMMUNOLOGY (2019)
Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?
Chiara Corti et al.
ADVANCES IN ANATOMIC PATHOLOGY (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.
Maria M. Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Siddhartha Srivastava et al.
CANCERS (2019)
LBA-002Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
J Tabernero et al.
ANNALS OF ONCOLOGY (2019)
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial
Kenji Tamura et al.
CANCER SCIENCE (2019)
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy
Emily N. Prendergast et al.
GYNECOLOGIC ONCOLOGY (2019)
Microsatellite instability diagnosis using the fully automated Idylla platform: feasibility study of an in-house rapid molecular testing ancillary to immunohistochemistry in pathology laboratories
Laura Samaison et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immunotherapy for hepatocellular carcinoma: Current and future
Michael P. Johnston et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorena Incorvaia et al.
ADVANCES IN THERAPY (2019)
Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors
Ewelina Grywalska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
Filippo Pietrantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy
Nicolas J. Llosa et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
N. Stjepanovic et al.
ANNALS OF ONCOLOGY (2019)
Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future
Hitomi Yamashita et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer
Camille Evrard et al.
CANCERS (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
Genetic Testing in Kidney Cancer Patients: Who, When, and How?
Sandy T. Lui et al.
EUROPEAN UROLOGY FOCUS (2019)
Microsatellite Instability in Glioblastoma: Is It Really Relevant in Tumor Prognosis?
Merih Tepeoglu et al.
TURKISH NEUROSURGERY (2019)
Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation
Aoife J. McCarthy et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2019)
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
Lorena Incorvaia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
LBA-005KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
K Shitara et al.
ANNALS OF ONCOLOGY (2018)
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Zishuo I. Hu et al.
CLINICAL CANCER RESEARCH (2018)
Hepatocellular carcinoma in the era of immunotherapy
Hao-Wen Sim et al.
CURRENT PROBLEMS IN CANCER (2018)
Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future
Alex B. Blair et al.
CURRENT PROBLEMS IN CANCER (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Landscape of Tumor Mutation Load, Mismatch RepairDeficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Mohamed E. Salem et al.
MOLECULAR CANCER RESEARCH (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience
Zhaohui Jin et al.
ONCOLOGIST (2018)
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
Ari Vanderwalde et al.
CANCER MEDICINE (2018)
Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors
Bobby Daly et al.
JAMA ONCOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries
Erbao Chen et al.
JOURNAL OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN
Yoshiaki Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
935PDPreliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
A Oaknin et al.
ANNALS OF ONCOLOGY (2018)
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review
Lidia Rita Corsini et al.
EXPERT OPINION ON DRUG SAFETY (2018)
A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.
Eileen Mary O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma
Vincent P. Groot et al.
ANNALS OF SURGERY (2018)
Microsatellite instability evaluation by automated microfluidic electrophoresis: an update
Francesco Pepe et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
Francesco Soria et al.
WORLD JOURNAL OF UROLOGY (2017)
Global Burden of Urologic Cancers, 1990-2013
Geolani W. Dy et al.
EUROPEAN UROLOGY (2017)
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Sebastien Antoni et al.
EUROPEAN UROLOGY (2017)
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives
Salvatore Giovanni Vitale et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification
Kentaro Inamura
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Novel Implications in Molecular Diagnosis of Lynch Syndrome
Raffaella Liccardo et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2017)
A molecular portrait of microsatellite instability across multiple cancers
Isidro Cortes-Ciriano et al.
NATURE COMMUNICATIONS (2017)
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
Brooke E. Howitt et al.
ONCOIMMUNOLOGY (2017)
Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome
N. Jewel Samadder et al.
JAMA ONCOLOGY (2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).
Gini F. Fleming et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
N. Colombo et al.
ANNALS OF ONCOLOGY (2016)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma
Fabrizio Bronte et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
Zsofia K. Stadler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Valerie Lee et al.
ONCOLOGIST (2016)
Genetic alterations in hepatocellular carcinoma: An update
Zhao-Shan Niu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
New insights into the mechanism of DNA mismatch repair
Gloria X. Reyes et al.
CHROMOSOMA (2015)
Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis
Colin M. Court et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2015)
New clinical advances in immunotherapy for the treatment of solid tumours
Valentina A. Zavala et al.
IMMUNOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
E. Bajetta et al.
ANNALS OF ONCOLOGY (2014)
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Beifang Niu et al.
BIOINFORMATICS (2014)
Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials
Florian Eckel et al.
CHEMOTHERAPY (2014)
Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers
Nathalia C. Campanella et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2014)
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?
Daniele Fanale et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'Care for CMMRD' (C4CMMRD)
Katharina Wimmer et al.
JOURNAL OF MEDICAL GENETICS (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations
Daniele Fanale et al.
ONCOLOGY (2013)
Era of universal testing of microsatellite instability in colorectal cancer
Xuchen Zhang et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2013)
Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications
Frank A. Sinicrope et al.
CLINICAL CANCER RESEARCH (2012)
Reflex Immunohistochemistry and Microsatellite Instability Testing of Colorectal Tumors for Lynch Syndrome Among US Cancer Programs and Follow-Up of Abnormal Results
Laura C. Beamer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial
Jeeyun Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2012)
Prospective Immunohistochemical Analysis of Primary Colorectal Cancers for Loss of Mismatch Repair Protein Expression
Steven A. Lee-Kong et al.
CLINICAL COLORECTAL CANCER (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Personalized medicine in oncology: the future is now
Richard L. Schilsky
NATURE REVIEWS DRUG DISCOVERY (2010)
Analysis of microsatellite instability in colorectal carcinoma by microfluidic-based chip electrophoresis
M. Odenthal et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Molecular Characterization of MSI-H Colorectal Cancer by MLH1 Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening
Jenny N. Poynter et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Upper Urinary Tract Urothelial Cell Carcinomas and Other Urological Malignancies Involved in the Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) Tumor Spectrum
Morgan Roupret et al.
EUROPEAN UROLOGY (2008)
Colorectal cancer risk in Crohn's disease
Hugh James Freeman
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors
Rosa M. Xicola et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
H. F. A. Vasen et al.
JOURNAL OF MEDICAL GENETICS (2007)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The multifaceted mismatch-repair system
J Jiricny
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors
O Buhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma
M Rouprêt et al.
UROLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme
R Martinez et al.
ONCOLOGY (2004)
Urothelial carcinoma of the upper urinary tract:: Inverted growth pattern is predictive of microsatellite instability
A Hartmann et al.
HUMAN PATHOLOGY (2003)
The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas
JM Cunningham et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
DNA chain length dependence of formation and dynamics of hMutSα.hMutLα.heteroduplex complexes
LJ Blackwell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
